Comments from our drug discovery AI technology and Life Science AI CTO Toyoshiba were published in the special feature "Surviving the" Natural "Era of AI Drug Discovery" by Nikkei Cross Tech and Nikkei Digital Health.

"The day when AI drug discovery becomes" commonplace "is approaching, and the new pharmaceutical industry is becoming a division of labor."

https://xtech.nikkei.com/atcl/nxt/column/18/01699/062800002/
https://xtech.nikkei.com/atcl/nxt/column/18/01699/062800002/?ST=ch_digitalhealth

"Awesome AI companies gather for drug discovery, making full use of robot laboratories and image recognition"

https://xtech.nikkei.com/atcl/nxt/column/18/01699/062900004/
https://xtech.nikkei.com/atcl/nxt/column/18/01699/062900004/?ST=ch_digitalhealth

"The important thing is" dialogue with people ", beyond the disconnection between drug discovery AI and humans."

https://xtech.nikkei.com/atcl/nxt/column/18/01699/063000005/
https://xtech.nikkei.com/atcl/nxt/column/18/01699/063000005/?ST=ch_digitalhealth